PAR 1.79% 27.5¢ paradigm biopharmaceuticals limited..

research reports and media, page-753

  1. 4,210 Posts.
    lightbulb Created with Sketch. 6686
    Edski1, good post, yes you bring up some good points there.

    It is somewhat hard for us to compare private and public companies.

    Your other point also warrants some discussion, namely the fact there, like our MPS solution can be worked in combination with Enzyme Replacement Therapy, is a chance we can actually work alongside such technologies as stem cells. Not only that but I am led to believe there are practitioners out there that are combining the two treatments and I'm investigating this field in the background. I'll report back once I have any more details but this also is a possibility that might work for us as opposed to any necessary direct competition.

    I do think we will have a good slice of the OA market once our final results are out, once patients start trying us out in numbers..its still a few years off in terms of any real scale, but at least in Aussie-land next year this process should start under the TGA for OA and hopefully in the space of MPS once approved by the FDA which should happen a lot quicker and earlier than the large OA program.




 
watchlist Created with Sketch. Add PAR (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.